Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences GILD. And retail traders should know.

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...

Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made by employees — as the company expanded its attack on HIV, cancer and ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $130.00.

Bearish flow noted in Gilead (GILD) with 1,949 puts trading, or 1.3x expected. Most active are 4/4 weekly 107 puts and Apr-25 109 puts, with ...

Drug regulator through executive order issued last August paved way for direct launch of certain categories of drugs approved ...

Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experienceWALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a ...

Bluebird Bio (BLUE) came out with a quarterly loss of $23.74 per share versus the Zacks Consensus Estimate of a loss of $6.60. This compares to loss of $15.60 per share a year ago. These figures are ...

Building the world's largest biobank with data from global populations to accelerate biomarker and drug discovery and ...